Financial Architects Inc purchased a new stake in shares of Teladoc Health Inc (NYSE:TDOC) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,485 shares of the health services provider’s stock, valued at approximately $230,000.

Other institutional investors have also recently made changes to their positions in the company. Baillie Gifford & Co. raised its position in Teladoc Health by 52.6% during the fourth quarter. Baillie Gifford & Co. now owns 5,732,223 shares of the health services provider’s stock valued at $479,901,000 after purchasing an additional 1,974,923 shares during the period. Norges Bank purchased a new stake in Teladoc Health during the fourth quarter valued at approximately $51,004,000. Renaissance Technologies LLC purchased a new stake in Teladoc Health during the fourth quarter valued at approximately $45,435,000. Point72 Asset Management L.P. purchased a new stake in Teladoc Health during the fourth quarter valued at approximately $16,702,000. Finally, Goldman Sachs Group Inc. raised its position in Teladoc Health by 62.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 510,652 shares of the health services provider’s stock valued at $42,752,000 after purchasing an additional 196,237 shares during the period.

TDOC stock traded up $4.69 during midday trading on Friday, reaching $184.23. The stock had a trading volume of 3,965,867 shares, compared to its average volume of 2,965,044. The stock has a market cap of $14.19 billion, a PE ratio of -136.47 and a beta of 0.44. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.14 and a current ratio of 6.14. The firm has a fifty day simple moving average of $168.37 and a two-hundred day simple moving average of $114.81. Teladoc Health Inc has a 52-week low of $53.46 and a 52-week high of $203.85.

Teladoc Health (NYSE:TDOC) last issued its earnings results on Wednesday, April 29th. The health services provider reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.05). The firm had revenue of $180.80 million during the quarter, compared to analysts’ expectations of $180.64 million. Teladoc Health had a negative return on equity of 10.60% and a negative net margin of 16.24%. The business’s revenue was up 40.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.43) EPS. On average, sell-side analysts predict that Teladoc Health Inc will post -1.14 EPS for the current fiscal year.

In related news, CMO Stephany Verstraete sold 93,597 shares of Teladoc Health stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $169.63, for a total value of $15,876,859.11. Following the completion of the transaction, the chief marketing officer now owns 106,837 shares in the company, valued at approximately $18,122,760.31. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Andrew Turitz sold 14,122 shares of Teladoc Health stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $168.41, for a total value of $2,378,286.02. Following the completion of the transaction, the senior vice president now owns 12,552 shares of the company’s stock, valued at approximately $2,113,882.32. The disclosure for this sale can be found here. Insiders have sold a total of 208,252 shares of company stock valued at $35,286,838 in the last quarter. Company insiders own 3.42% of the company’s stock.

Several brokerages have recently weighed in on TDOC. UBS Group increased their price target on Teladoc Health from $119.00 to $185.00 and gave the stock a “neutral” rating in a report on Thursday, April 30th. Stifel Nicolaus increased their price target on Teladoc Health from $135.00 to $144.00 and gave the stock a “hold” rating in a report on Thursday, April 30th. SVB Leerink increased their price target on Teladoc Health from $180.00 to $197.00 and gave the stock an “outperform” rating in a report on Thursday, April 30th. Zacks Investment Research downgraded Teladoc Health from a “buy” rating to a “hold” rating and set a $202.00 price target on the stock. in a report on Wednesday. Finally, Robert W. Baird increased their price target on Teladoc Health from $130.00 to $135.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Fifteen research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $162.54.

Teladoc Health Company Profile

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Read More: Are sell-side analysts objective?

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.